VOOZH about

URL: https://link.springer.com/article/10.1007/BF02308377?error=cookies_not_supported&code=863a1612-a5e5-4665-b2a2-4051490d7cf9

⇱ Lorcainide treatment of Wolff-Parkinson-White syndrome in children and adolescents | Pediatric Cardiology | Springer Nature Link

Skip to main content

Lorcainide treatment of Wolff-Parkinson-White syndrome in children and adolescents

  • Original Articles
  • Published:

Summary

Lorcainide was used in 17 children and adolescents aged 14 days to 18 years (mean 6.8 years) with the preexcitation syndrome (W-P-W type). Lorcainide was able to control attacks of supraventricular tachycardia in eight of 11 patients with the W-P-W syndrome and tachyarrhythmias. Long-term maintenance therapy prevented new attacks of tachyarrhythmia for an average period of nine (5–15) months in all seven patients who tolerated lorcainide administration. Normalization of the W-P-W pattern was reached in nine of 11 children with the W-P-W syndrome who had tachyarrhythmias and in three of six asymptomatic children with the ECG pattern of W-P-W. Single effective doses ranged from 12.5 mg orally in the neonates to 100 mg in the adolescents. The effect of lorcainide on the ECG usually appeared 2 h after the oral administration of the drug. Dizziness in three with insomnia and vomiting in one patient complicated the treatment. No drug-associated abnormalities in blood cell counts and biochemical values were identified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References

  1. Amery WK, Heykants JJP, Xhonneux R, Towse G, Oettel P, Cough DA, Janssen PAJ (1981) Lorcainide (R 15 889): a first review.Acta Cardiol 36:207–234

    CAS  PubMed  Google Scholar 

  2. Bär F, Farré J, Gorgels A, Wellens H (1981) Electrophysiological effects of lorcainide: a new antiarrhythmic drug. Observations in patients with and without pre-excitation.Br Heart J 45:292–298

    PubMed  Google Scholar 

  3. Cocco G, Strozzi C (1978) Initial clinical experience of lorcainide, a new antiarrhythmic agent.Eur J Pharmacol 14:105–109

    CAS  Google Scholar 

  4. Jordan J, Yamaguchi I, Mandel WJ (1978) Elimination of the delta wave in the Wolff-Parkinson-White syndrome.Chest 72:215–218

    Google Scholar 

  5. Kasper W, Meinertz T, Kersting F, Löogen H, Lang K, Just H (1979) Electrophysiological actions of lorcainide in patients with cardiac disease.J Cardiovasc Pharmacol 1:343–352

    CAS  PubMed  Google Scholar 

  6. Kesteloot H, Stroobandt R (1977) Clinical experience with lorcainide (R 15 889), a new antiarrhythmic drug.Arch Int Pharmacodyn Ther 230:225–234

    CAS  PubMed  Google Scholar 

  7. Klotz U, Müller-Seydlitz P, Heimburg P (1979) Disposition and antiarrhythmic effect of lorcainide.Int J Clin Pharmacol Biopharm 17:152–158

    CAS  PubMed  Google Scholar 

  8. Manz M, Steinbeck G, Lüderitz B (1982) Electrophysiological effects of lorcainide in sinoatrial disease and in Wolff-Parkinson-White syndrome.Eur Heart J 3:56–66

    CAS  PubMed  Google Scholar 

  9. Meinertz T, Kasper W, Kersting F, Just H, Bechtold H, Jämchen F (1979) Clinical pharmacokinetics of the anti-arrhythmic drug lorcainide. II. Plasma concentration-effect relationship.Clin Pharmacol Ther 26:196–204

    CAS  PubMed  Google Scholar 

  10. Meinertz T, Kersting F, Kasper W, Just H, Bechtold H, Jänchen F (1980) Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease.Eur J Clin Pharmacol 18:461–465

    Article  CAS  PubMed  Google Scholar 

  11. Rosenbaum FF, Hecht HH, Wilson FN, Johnston FD (1945) The potential variations of the thorax and the esophagus in anomalous atrioventricular excitation (Wolff-Parkinson-White syndrome).Am Heart J 29:281

    Article  Google Scholar 

  12. Van Walleghem W, Stroobandt R, Terryn R, Vandervoort R, Popeye R (1980) Lorcainide in cardiologic practice: a multicentre experience with special reference to safety aspects. Clinical Research Report R 15 889/37

Download references

Author information

Authors and Affiliations

  1. Center for Pediatric Cardiology and Cardiovascular Surgery, University Hospital Motol, 151 12 Praha 5-Motol, Prague, Czechoslovakia

    Milan Šamánek & Helena Bartáková

  2. 2nd Department of Pediatrics, University Hospital Motol, Prague, Czechoslovakia

    Věra Hroboňová

Authors
  1. Milan Šamánek
  2. Věra Hroboňová
  3. Helena Bartáková

About this article

Cite this article

Šamánek, M., Hroboňová, V. & Bartáková, H. Lorcainide treatment of Wolff-Parkinson-White syndrome in children and adolescents. Pediatr Cardiol 8, 3–9 (1987). https://doi.org/10.1007/BF02308377

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1007/BF02308377

Key words